Ерибулин Зентива

Ерибулин Зентива (eribulin mesylate) is an antineoplastic agent used for cancer treatment. This chemotherapy medication is administered intravenously and works by stopping cancer cell growth. It is prescribed under the brand name Halaven in some regions.

Eribulin Mesylate is primarily used to treat certain types of cancer, including metastatic breast cancer and liposarcoma. It may be prescribed when other treatments have not been effective. This medication targets rapidly dividing cancer cells to slow disease progression. Patients should discuss specific treatment plans with their healthcare provider.

Eribulin Mesylate works by interfering with the growth of cancer cells, which can help reduce tumor size or slow its spread. Common effects include changes in blood cell counts, fatigue, or nausea. These effects vary by individual and should be monitored by a healthcare professional.

This medication is for intravenous use only and should be administered by a healthcare provider. Patients should inform their doctor about all medications, supplements, and medical conditions before starting treatment. Regular blood tests may be required to monitor safety and effectiveness.

Eribulin Mesylate may interact with other drugs, including CYP3A4 inhibitors or inducers, which can affect its levels in the body. Patients should avoid grapefruit products and discuss all current medications with their doctor. Alcohol and certain supplements may also interact.